





Cite this: DOI: 10.1039/c7tb00855d

Received 28th March 2017,
Accepted 6th July 2017

DOI: 10.1039/c7tb00855d

rsc.li/materials-b

Fullerenes in biology and medicine

Edison Castro,  Andrea Hernandez Garcia, Gerardo Zavala and Luis Echegoyen *

Fullerenes and related carbon based derivatives have shown a growing relevance in biology and medicine, mainly due to the unique electronic and structural properties that make them excellent candidates for multiple functionalization. This review focuses on the most recent developments of fullerene derivatives for different biological applications.

1. Introduction

The research on fullerene C₆₀ started in 1985 when Kroto, Curl and Smalley discovered the third allotropic form of carbon after diamond and graphite.¹ The first functionalization reaction² was reported soon after the fullerenes were synthesized in macroscopic amounts in 1990.³ Functionalized fullerenes exhibit improved solubility and different chemical and physical properties that allow their applications in multiple fields.⁴ In 1993 Wudl and coworkers reported the first water-soluble fullerene derivative 1 (Fig. 1) that inhibited the activity of HIV-1 protease (HIV-1 PR), as determined from the interaction of this compound and HIV-1 PR based on an *in vitro* assay.⁵ Since then, efficient synthetic methods for fullerene functionalization have been developed.^{6,7}




Fig. 1 First water-soluble and biologically active fullerene derivative reported.

Functionalization with bioactive compounds that exhibit affinity to certain nucleic acids, proteins or cell receptors such as peptides^{8–10} or saccharides,^{11,12} functionalization with polar or ionic groups such as hydroxyl,^{13,14} carbonyl^{15–17} or quaternary ammonium salts,^{18,19} and encapsulation with macromolecules^{20,21} are the most common approaches to synthesize water-soluble fullerene derivatives for biomedical applications.^{22–26}

Department of Chemistry, University of Texas at El Paso, 500 West University Avenue, El Paso, TX, USA. E-mail: echegoyen@utep.edu



Edison Castro

Edison Castro was born in Narino, Colombia. He obtained his BSc from the Universidad de Narino, Colombia, in 2008, and his MS degree from the Universidad del Valle in Cali, Colombia, in 2011. Currently he is pursuing his PhD under the supervision of Prof. Luis Echegoyen at The University of Texas at El Paso. His current research interests include the synthesis of fullerene derivatives for photovoltaic and biological applications, and the design of perovskite solar cells.



Andrea Hernandez Garcia

Andrea Hernandez Garcia is an undergraduate student expecting to receive her BS at the University of Texas at El Paso in Cellular and Molecular Biochemistry in the Spring of 2017. She is currently an undergraduate researcher working on the synthesis of new fullerenes for photovoltaic and biological applications under the mentorship of Prof. Luis Echegoyen.

Several reviews have been published that summarize the biological applications of fullerene derivatives.^{23,27,28} In this review, we summarize the biological properties of active fullerene derivatives reported during the last 3 years along with their biomedical applications.

2. Properties

The three dimensional shape of fullerenes results in unique chemical and physical properties. Chemical functionalization can be easily achieved to alter the properties of the new compounds.^{7,29–31}

2.1 Chemical properties

Due to the spherical shape of fullerenes, carbon atoms are highly pyramidalized and are thus highly reactive. The conjugated carbon atoms deviate from planarity by orbital rehybridization of the sp^2 orbitals to $sp^{2.27}$ orbitals with a p-character gain.³²

C_{60} and C_{70} fullerenes can be reversibly reduced with up to six electrons.³³ This high electron affinity results from the presence of triply degenerate low-lying lowest unoccupied molecular orbitals (LUMOs).³⁴

The chemical reactivity of fullerenes is similar to that of an electron deficient olefin, yielding cycloaddition reaction products³⁵ where the addition takes place at a 6,6 ring junction. Additions to 5,6 ring junctions have been reported as a result of rearrangements after the initial kinetic addition to a 6,6 bond.³²

2.2 Physical properties

Fullerenes can resist high pressures and return to their original shape after being subjected to over 3000 atmospheres.³⁶ It was theoretically calculated that a single C_{60} molecule has an effective bulk modulus of 668 GPa when compressed to 75% of its size. This property makes fullerenes harder than steel and diamond, whose bulk moduli are 160 GPa and 442 GPa, respectively.³⁷

Fullerenes are the only known allotropes of carbon that can be dissolved in some common solvents at room temperature.

Large indices of refraction, a dielectric constant of approximately 4, large molecular volumes, and the Hildebrand solubility parameter equal to $10 \text{ cal}^{1/2} \text{ cm}^{-3/2}$ have been reported for C_{60} solutions.³⁸

3. Antiviral activity

3.1 Anti-HIV-1

In the absence of an effective vaccine, antiretroviral therapy (ART) is the only therapeutic tool that can be used to treat HIV-1 infection. Usually, this protocol combines a nucleoside reverse-transcriptase inhibitor (RTI) with either a non-nucleoside RTI or a protease inhibitor (PI).³⁹ These ARTs efficiently suppress the spread of HIV in patients; however, the emergence of multidrug resistant viruses is still a serious problem in anti-HIV therapy.^{39–41} Therefore, the development of new type of anti-HIV drugs that are structurally distinct from the currently used pharmaceutical agents is a critical need.

It has been demonstrated *in vivo* and *in vitro* that impairment of viral maturation is a powerful strategy to block HIV-1 replication. HIV-1 maturation can be inhibited by PIs or by maturation inhibitors (MIs). The latter can bind to Gag and affect its processing or to CA, thus impairing core assembly.⁴² Currently, there are no maturation inhibitors that are used clinically.⁴³

HIV PIs work by specifically binding to the active site and blocking the activity of the protease. For 24 years, it was assumed that fullerene inhibition of HIV-1 was only due to the interaction between the fullerene and the hydrophobic pocket of this enzyme, as determined by *in silico* predictions combined with an *in vitro* assay.^{5,44} This paradigm was recently challenged by the fact that C_{60} and C_{70} fullerene derivatives do not inhibit the activity of HIV-1 PR at concentrations (3 μM) that potentially inhibit HIV-1 infection (see structures in Fig. 2).^{19,45} Additionally, fullerenes 2–6 inhibited HIV-1 viruses resistant to multiple PR and MIs. Although the mechanism of action is not known, it was suggested to be *via* impairment of virus maturation as a result of a strong interaction with the



Gerardo Zavala

Gerardo Zavala is an undergraduate student currently pursuing a BS in Chemistry at The University of Texas at El Paso. While studying there, he joined the BUILDing SCHOLARS program, a research-intensive scholarship program. He joined Prof. Luis Echegoyen's research group in May 2016. His current research interests include the synthesis and characterization of fullerene derivatives for their application in perovskite solar cells as well as their biological applications.



Luis Echegoyen

Prof. Luis Echegoyen obtained both his BSc and PhD from the University of Puerto Rico in Rio Piedras. After several professorships at the Universities of Puerto Rico, Maryland, and Miami he was appointed Chair of the Department of Chemistry at Clemson University, in South Carolina. Later he served as Division Director for Chemistry at the National Science Foundation for 4 years (2006–2010) and more recently, he became the Robert A. Welch Professor of Chemistry at the University of Texas-El Paso in 2010. His research interests include fullerene chemistry, electrochemistry, and supramolecular chemistry, with a special emphasis on photovoltaics and endohedral fullerenes.




Fig. 2 Maturation inhibitor fullerene derivatives.

immature capsid in pull-down experiments.¹⁹ Fullerene derivatives 2–6 were reported to exhibit no cytotoxicity; therefore they are

excellent candidates as anti-HIV-1 agents.^{19,45} Due to the solubility of [60]fullerene-peptide derivatives, they have also been considered as potential inhibitors of HIV-1 replication.⁴⁶ Using drug screening and docking calculations, a database of PI [60]fullerene derivatives and their binding constants was constructed.⁴⁷ Strom *et al.*⁴⁸ determined that improved inhibition can be achieved with minor modifications of both the peptide and the amino acid structure.

PR inhibition by [60]fullerene peptides 7–11 (Fig. 3) was predicted *in silico*, and binding constants were calculated experimentally using a cell-free fluorescence resonance electron transfer (FRET) assay.⁴⁸ Recently Khakina *et al.*⁴⁹ reported a new fullerene derivative 12 (Fig. 3) that exhibits low cytotoxicity (above 100 μM) and blocks HIV-1 infection *in vitro*, with a minimum inhibitory concentration (EC_{50}) of 4.6 μM . Compound 12 showed higher anti-HIV-1 activity than its pentasulfide analogue $\text{C}_{60}(\text{SC}_2\text{H}_4\text{COOK})_5\text{H}$ ($\text{EC}_{50} = 45.2 \mu\text{M}$).⁵⁰ However, no mechanism of action was proposed for this antiviral compound.

As previously mentioned, HIV-1 reverse transcriptase (RT) is required for early proviral DNA synthesis and thus inhibition of




Fig. 3 Structure of anti-HIV-1 [60]fullerene derivatives 7–24.

this enzyme results in inhibition of virus replication. The HIV-1 RT inhibitory activity of cationic, anionic and zwitterionic fullerene derivatives has been previously reported,⁵¹ where cationic fullerenes showed lower activity. Yasuno *et al.*⁵² reported for the first time that pyridine/pyridinium-type fullerene derivatives 13–15 (Fig. 3) without any carboxylic acid inhibit HIV-1 RT in a cell-free environment, with no cytotoxicity and clearly showing that the fullerene cage was crucial for the inhibition of HIV-RT. Compounds 16–24 (Fig. 3) were also active against HIV-RT.

3.2 Bacterial and viral inhibition *via* anti-adhesion to host cells

3.2.1 Anti-bacterial inhibition. Molecular recognition between carbohydrates and proteins plays an essential role in many biological processes.⁵³ One example is bacterial infection that begins with bacterial adhesion to host cells. Inhibition of this step using glycoclusters or glycodendrimers that mimic multivalent carbohydrates at the cell surface is one of the most studied mechanisms over the last decade.⁵³ Protein-carbohydrate interactions exhibit high specificity and weak affinities toward carbohydrate ligands. It has been demonstrated that ligand multivalency increases the low binding affinities of monovalent glycosides.⁵³

Nierengarten *et al.*⁵⁴ have demonstrated that fullerenes are very attractive spherical scaffolds that can be functionalized with carbohydrates using a very straightforward approach. Using this synthetic approach Sánchez-Navarro *et al.*⁵⁵ reported new hexakis adducts of C₆₀ endowed with 24 sugar moieties. The carbohydrate recognition of these new derivatives by a lectin was investigated by isothermal titration calorimetry (ITC) experiments. The results showed that fullerene C₆₀ is an efficient platform for the globular presentation of carbohydrates for protein-carbohydrate interactions. Buffet *et al.*⁵⁶ reported the synthesis and the multivalent effect against two lectins, LecB and RSL (compounds 25A–25E) (Fig. 4). The results showed higher affinity for compound 25E, which contains higher valency and a longer linker between the core and the sugar. This fullerene derivative appears to be one of the best inhibitors for both lectins.

3.2.2 Anti-Ebola-virus. Ebola virus infection causes severe and often fatal hemorrhagic fever in humans and other mammals. The 2013–2015 Ebola virus epidemic in West Africa⁵⁷ caused at least 11 310 confirmed deaths.⁵⁸ The virus initiates infection by binding to host receptors through its glycoprotein surface. DC-SIGN, a C-type lectin receptor, has been proposed as one of




Fig. 5 Giant globular multivalent glycofullerenes. Reprinted by permission from Macmillan Publishers Ltd: Nature Chemistry, Muñoz *et al.*¹² Copyright (2016).

the receptors for cell entrance for several microorganisms that contain glycoconjugates on their envelope.

Due to the important role of DC-SIGN in the first step of viral infections such as HIV and Ebola,^{59,60} the discovery of new compounds with higher affinity for this receptor is of great importance.

The sugar residues in fullerenes act as solubilizing groups and induce remarkable biological properties.^{56,61–64} In 2013, Luczkowiak *et al.*⁶⁵ reported for the first time the potential application of glycodendrofullerenes as antiviral agents. In 2016 Muñoz *et al.*¹² reported the synthesis of hexakis adducts of fullerene C₆₀, with the most effective dendrimeric growth (compounds 26–28) (Fig. 5). Compounds 25 and 27 showed very potent antiviral activity in the range of nM and pM concentrations, respectively. The results clearly showed the dependence of the inhibition effect on mannoses, and compound 26 with 120 galactoses was not active.¹²

4. Photodynamic therapy

Photodynamic therapy (PDT) is a clinically approved therapeutic technique for the treatment of multiple diseases, mainly cancer.⁶⁶ It relies on the photoexcitation of an inactive photosensitizer (PS) at a wavelength that matches the absorption of the PS, leading to localized generation of cytotoxic reactive oxygen species (ROS). ROS cause oxidative damage to nearly all types of biomolecules (proteins, lipids and nucleic acids) and tumor cell death.⁶⁷ PDT has remarkably improved selectivity and fewer side effects than traditional anticancer therapies.⁶⁸




Fig. 4 Fucofullerenes and their corresponding monomeric controls. Reproduced from ref. 56 with permission from The Royal Society of Chemistry.

Fullerenes C_{60} and C_{70} can effectively be excited to their triplet state and can efficiently convert 3O_2 to 1O_2 .^{69,70} Hamblin and coworkers⁷¹⁻⁷⁴ have tested electron-transfer reactions of photoexcited cationic fullerene derivatives both *in vitro* and *in vivo* on animal models with localized bacterial infections. The activity of compound **29** (Fig. 6) was significantly improved by the addition of potassium iodide (KI) salt, although how the iodide anion enhances the antibacterial effects is not completely understood.⁷²

Functionalization of C_{60} with *n*-butyl sulfonic acid salts to form self-assembled molecular micellar nanospheres, as with compound **30** (Fig. 6), was found to retain high efficiency in generating singlet oxygen upon irradiation with visible light.⁷⁵ The mechanism was correlated to the facile intermolecular triplet energy-transfer from photoexcited $^330^*$ to molecular

oxygen. Guan *et al.*⁷⁶ reported nanovesicles of fullerene C_{70} tris-adducts conjugated with chlorin e6 (Ce6), compounds **31** (Fig. 6), through an oligo ethylene glycol linker. This system significantly enhanced both cellular uptake efficiency and PDT *in vitro* and *in vivo*. Biocompatibility and total body release of these particles are among the advantages of these conjugated nanovesicles.⁷⁶

The production of ROS in mitochondria plays a critical role in photodynamic therapy. Li *et al.*⁷⁷ investigated the generation of additional endogenous ROS in mitochondria using a chitosan oligosaccharide grafted fullerene conjugate (CS- C_{60}) compound **32** (Fig. 6). The ROS generated at low doses of CS- C_{60} was concentrated in mitochondria, enhancing the inhibition of human malignant melanoma (A375) cells. Rotenone assays showed that PDT-induced endogenous ROS was generated through an electron




Fig. 6 Fullerene derivatives for PDT applications.

transport chain (ETC).⁷⁷ Kim *et al.*⁷⁸ reported the synthesis of chitosan/fullerene nanogel compound **33** (Fig. 6) for efficient tumor therapy. At pH 7.4, electrostatic interactions between the pendant carboxylic acid groups of 2,3-dimethylmaleic acid (DMA) and the residual free amine groups of glycol chitosan (GC) resulted in the formation of multinanogel aggregates. Nevertheless, dissociation of the nanogel aggregates was observed at pH 5.0, resulting in improved singlet oxygen generation and elevated photodynamic tumor cell ablation.⁷⁸

Franskevych *et al.*⁷⁹ reported the cytotoxic effect of C₆₀ in combination with visible light irradiation on leukemic L1210 cell lines, both sensitive and resistant to cisplatin. Their results suggest that C₆₀-mediated photodynamic treatment is a good candidate for restoring drug-resistant leukemic cells induced to mitochondrial apoptosis. C₆₀-RITC compound **34** (Fig. 6) was synthesized to monitor C₆₀ entry into leukemic cells *via* confocal microscopy.⁷⁹

Mion *et al.*⁸⁰ reported the synthesis of fullerene compound **35** (Fig. 6) for photodynamic therapy and imaging applications. Although it was not completely isolated, its presence was confirmed by MALDI-TOF. Ershova *et al.*⁸¹ studied the cytotoxicity and genotoxicity of a C₆₀ fullerene derivative functionalized with five residues of 3-phenylpropionic acid and a chlorine atom arranged around one cyclopentadienyl unit, compound **36** (Fig. 7), in diploid human embryonic lung fibroblasts (HELFs). It was found to cause complex time-dependent changes in ROS levels. At short exposure times, when it had not yet penetrated the cytoplasm, compound **36** considerably decreased ROS levels in the medium and on the surface of the cell membrane. Long-term exposure can induce secondary oxidative stress and possibly induce pulmonary fibrosis.




Fig. 7 Fullerene derivatives for photodynamic therapy.




Fig. 8 Exchange method used for the preparation of LMIC₆₀ derivatives. (a) Rapid mixing of two solutions and (b) injection. Reproduced from Ikeda *et al.*²¹ with permission from The Royal Society of Chemistry.

Fullerene C₆₀ derivatives **37–39** (Fig. 7) were incorporated into liposomes using a fullerene exchange method involving the transfer of fullerenes from the cavity of two γ -cyclodextrin molecules to a liposome, as illustrated in Fig. 8.^{20,21}

The photodynamic activity of compound **38** incorporated into lipid membranes was much higher than that of compounds **37** and **39** under the same conditions. The high photodynamic activity of compound **38** was attributed to its increased ¹O₂ generating ability, as determined by 9,10-anthracenediyl-bis-(methylene)dimalonic acid (ABDA) as a detector.⁸²

Wang *et al.*⁸³ reported the synthesis and DNA cleavage activity of a β -cyclodextrin fullerene C₆₀, compound **40** (Fig. 7). The DNA cleaving ability was tested by using pBR322 plasmid DNA containing more than 90% supercoiled DNA, NADH and compound **40**. DNA cleavage was observed after 4 h of visible light irradiation, but it was not observed under the condition of no light in the presence or absence of both NADH and compound **40**. Additionally, compound **40** showed no significant cytotoxicity in human neuroblastoma SH-SY5Y cells, as determined by a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay.⁸³

5. Antioxidant properties of fullerene derivatives

Functionalization of fullerenes with polar functional groups is one of the approaches to overcome their insolubility in water,

while retaining their unique properties and to enhance their biological activities.^{84–86} Fullerenes are commonly classified as “radical sponges”,⁸⁷ due to their remarkable reactivity with free radicals.^{88–97}

The antioxidant capacity of fullerlenols and their derivatives has been measured by DMPO-spin trap/ESR methods, and by using the β -carotene and DPPH assays.⁹⁸ However, the kinetics and radical scavenging mechanisms of these compounds are still not completely understood. Density functional theory (DFT) calculations suggest that fullerlenols with 6 and 12 hydroxyl groups are the most stable derivatives.⁹⁹

Ueno *et al.*¹⁰⁰ studied the antioxidant activity of several hydroxylated fullerenols with 8, 10, 12, 24, 26, 36, and 44 hydroxyl groups by a β -carotene bleaching assay. The relative radical scavenging rate of fullerlenols toward radical species derived from linoleic acid under autoxidation conditions indicated that $C_{60}(OH)_{12}$ and $C_{60}(OH)_{44}$ reacted 1.62 and 1.54 times faster than β -carotene, respectively.

Based on the analysis of the possible products of both fullerlenols and C_{60} with radical species generated from methyl linoleate under autoxidation conditions, the authors proposed two antioxidant mechanisms dependent on the number of hydroxyl groups (Fig. 9).¹⁰⁰

One is C-addition, which includes the peroxy radical addition to a conjugated C=C double bond (mechanism A), and the other is H-abstraction, which involves hydrogen atom abstraction from –OH groups and the subsequent fullerene radical rearrangement to form an ether bridge (mechanism B). Fullerenol $C_{60}(OH)_{10}$ with more π -conjugated double bonds undergoes the C-addition mechanism similar to C_{60} , while fullerenol $C_{60}(OH)_{40}$ undergoes H-abstraction because of the less π -conjugated double bonds.

Grebowski *et al.*¹⁰¹ studied the rate constants of highly hydroxylated fullerene $C_{60}(OH)_{36}$ interacting with hydroxyl radicals ($\cdot OH$) and hydrated electrons. The rate constant for the reaction of $C_{60}(OH)_{36}$ with $\cdot OH$ was $2.0 \times 10^9 \text{ dm}^3 \text{ mol}^{-1} \text{ s}^{-1}$, which




Fig. 9 Possible mechanisms for lipid peroxy radical (LOO^*) scavenging by fullerlenols $C_{60}(OH)_n$: (a) addition to C=C bonds and (b) H-abstraction from –OH groups. Adapted from Ueno *et al.*¹⁰⁰ (2014).




Fig. 10 Schematic illustration of the conjugation of fullerlenols on CNC. Reprinted from Awan *et al.*¹⁰⁴ (2016), with permission from Springer.

was similar to that of $C_{60}(OH)_{18}$, $4.5 \times 10^{-8} \text{ dm}^3 \text{ mol}^{-1} \text{ s}^{-1}$.¹⁰² These results showed that the decreased number of π bonds, due to the larger number of OH groups attached to the fullerene, did not significantly affect the rate constant for the reaction with hydroxyl radicals.

Srdjenovic *et al.*¹⁰³ studied the influence of $C_{60}(OH)_{24}$ on Chinese hamster ovary cells (CHO-K1). Their results showed the strong antioxidant properties of $C_{60}(OH)_{24}$ influencing the cellular redox state and enzyme activities. Therefore, it reduces cell proliferation and was proposed as a cytoprotective agent.

Improved free radical scavenger properties were reported by Awan *et al.*¹⁰⁴ as a result of functionalization of $C_{60}(OH)_{30}$ on the surface of cellulose nanocrystals (CNCs). The immobilization appears to be due to the covalent interaction between the –OH groups on the CNC and π -conjugation of the fullerene. It was proposed that this results in a reduced tendency to form clusters and greater accessibility to the free radicals (Fig. 10).

Mitochondrial dysfunction is considered as a crucial mechanism of nanomaterial toxicity. Yang *et al.*¹⁰⁵ investigated the effects of $C_{60}(OH)_{44}$ on isolated mitochondria. The exposure of mitochondria to fullerene not only affected the respiratory chain but also damaged the inner membrane, allowing permeability to H^+ and K^+ in a concentration dependent manner.

6. Anti-cancer properties

Recent studies illustrate the wide range of avenues of the use of fullerenes as anticancer agents.^{106–113} Pyrrolidinium fullerene derivatives have been shown to induce mitochondrion- and caspase-dependent apoptosis through the generation of ROS in human promyeloleukaemia (HL-60) cells.¹¹⁴

It has also been reported that pyrrolidinium fullerene compounds 41–47 (Fig. 11) induced apoptotic cell death of cells mutated on JAK2 V617F, which show resistance to multiple anti-tumor drugs.¹¹⁵

The results showed that replacement of one hydrogen atom (compound 42) or the *N*-methyl group (compound 45) on




Fig. 11 Fullerene derivatives with anticancer properties.

compound **41** with a butyl group enhanced the ability of pyrrolidinium fullerenes to induce apoptosis in VF-Ba/F3 cells.¹¹⁵

Attachment of structural conjugate drugs to C₆₀ is a good strategy to confer biological activity to fullerenes.¹¹⁶ Magoulas *et al.*¹¹⁷ studied the properties of fullerene C₆₀ conjugated with one (**48**) and two (**49**) units of doxorubicin (DOX), a potent anticancer agent (Fig. 11). To avoid bis-adduct mixture of isomers, the authors opted for multiple arms on a mono-fulleropyrrolidine derivative (Fig. 11). These conjugates exhibited a comparable, but with a more delayed onset, antiproliferative effect compared to free (non-conjugated) DOX when incubated with MCF-7 cells under the same conditions.

Probably, after conjugate entrance into the cells, the drug must be released from the conjugate to become active.

The effect of sonodynamically activated pyrrolidine tris-acid fullerene derivative **50** (Fig. 11) in isolated sarcoma-180 cells and in mice bearing ectopically implanted colon 26 carcinoma was studied by Yumiko *et al.*¹¹⁸ The results showed 5-fold enhanced cell damage induced by ultrasonic exposure in the presence of compound **50** (80 μM) and the growth of the implanted colon 26 carcinoma was decreased in both *in vitro* and *in vivo* experiments. Histidine, a singlet oxygen and hydroxyl radical scavenger, was used to determine whether reactive oxygen species participate in sonodynamically inducing cell damage. The results suggest that the enhancement was due to the generation of active oxygen. This work is the first step for clinical applications of sonodynamic therapy using fullerene derivatives.¹¹⁸

7. Immunological properties

It has been reported that C₆₀ fullerene derivatives, when conjugated to bovine thyroglobulin or rabbit serum albumin, induce the production of fullerene-specific IgG antibodies in immunized mice.^{119–122} Turabekova *et al.*¹²³ reported a computational study where C₆₀ fullerenes can act as ligands for toll-like receptors and therefore can be recognized as pathogens, inducing proinflammatory immune response.

The potential suppressive effects of compound **50** (Fig. 11) and fulleranol (C₆₀(OH)₃₆) were studied on many *in vitro* and




Fig. 12 Fullerene derivatives with immunological properties.

in vivo models of inflammatory diseases by Hirai *et al.*¹²⁴ Their results suggest that both fullerene derivatives can suppress acquired immune responses that require T cells *in vitro*. Additionally, compound **50** suppressed ovalbumin-specific antibody production and ovalbumin specific T cell responses *in vivo*.

Funakoshi-Tago *et al.*¹²⁵ demonstrated that bis-malonic acid fullerene derivative compound **51** (Fig. 12) suppressed interleukin 33 (IL-33) induced expression of IL-6 in bone marrow-derived mast cells (BMMC). IL-33 works both intra- and extracellularly as a nuclear factor regulating gene transcription and as a traditional cytokine, respectively.¹²⁶ Intracellular IL-33 is thought to be released after cell necrosis to alert the immune system of tissue damage or stress, and extracellular IL-33 coordinates immune defence and repair mechanisms while also initiating differentiation of helper T cells as the adaptive immune response is triggered.¹²⁷ This has attracted attention as a new target for the treatment of inflammatory diseases.¹²⁸

Pacor *et al.*¹²⁹ studied the interaction between fullerene derivatives **52** and **53** (Fig. 12) and cells of the immune system and their results stress the important role of fullerene derivatives in the control of inflammatory and cancer diseases.

52 showed biological properties that make it compatible with monocytes and macrophages, remarking its potential use to deliver compounds capable of modulating the immune responses or as a vehicle to deliver anticancer drugs.¹²⁹ Compounds **52** and **53** were more active on neoplastic proliferating cells than on circulating monocytes. Compound **53** is more toxic than compound **52** against the tested cells. At active doses on tumor cells, **53** was found in the cell cytoplasm without altering the cell membrane permeability. It was not clear why **53** was toxic to macrophages, but it can be attributed to the high concentration to which the cells were exposed rather than a negative effect on mitochondrial function.

8. Biological applications of endohedral metallofullerenes (EMFs)

EMFs are fullerenes that encapsulate metal atoms or clusters. Some of the encapsulated species can be used in diagnostic or tumor therapy, but these properties are limited due to their high toxicity. It is well known that the carbon cages of EMFs prevent the encapsulated species from being released into or reacting with the biological systems. Additionally, they retain enough reactivity for exohedral-functionalization that transforms the hydrophobic cage into more hydrophilic compounds




Fig. 13 Functionalization of Gd-EMFs. Reprinted with permission from Li *et al.*¹³⁰ Copyright (2016) Wiley-VCH and Sons.

as illustrated in Fig. 13.¹³⁰ The recent progress with gadolinium (Gd) based EMFs for biomedical applications is described.

8.1 Magnetic resonance imaging (MRI) contrast agents

Gd-based metallofullerenes (Gd-MF) have attracted special interest as MRI contrast agents due to their high paramagnetic properties and high relaxivity.^{131–134}

Murphy *et al.*¹³⁵ reported the application of Gd₃N@C₈₀ for *in vitro* and *in vivo* imaging and tracking of human amniotic fluid-derived stem cells within lung tissue. Gd₃N@C₈₀ was able to specifically bind to damaged lung tissue, although the imaging intensity dissipated a month after the initial dosage. This is the first reported use of a Gd-EMF to label and deliver exogenous cells to tissue and perform longitudinal MRI to evaluate the dynamics of cell homing, migration and clearance.

Zhang *et al.*¹³⁶ reported hydroxylated Gd₃N@C_s-C₈₄, an “egg-shaped” EMF with fused pentagons on its cage that increase the dipole moment of the compound and thus its solubility in water. Moreover, it exhibited enhanced relaxivity. Meanwhile, Li *et al.*¹³⁷ reported two hydroxylated derivatives, Gd@C₈₂(O)₁₀(OH)₁₆ and Gd@C₈₂(O)₁₀(OH)₂₂, that exhibited similar properties to those of Gd₃N@C_s-C₈₄.

Xiao *et al.*¹³⁸ synthesized a new Gd endohedral fullerene derivative, IL-13-TAMRA-Gd₃N@C₈₀(OH)₃₀(CH₂CH₂COOH)₂₀, functionalized with a cytokine IL-3 that increases its selectivity for IL-13R α 2 receptors. These receptors are important markers for chronic post-traumatic osteomyelitis, an opportunistic infection of the bone marrow. Gd-EMFs functionalized with the same IL-13 cytokine and additional positively charged amino groups (NH₃⁺) have also been used in imaging glioblastoma tumor cells as represented in Fig. 14.¹³⁹ The positively charged groups, coupled with the IL-3 functionalization, increased selectivity for tumor U-251 cells. Li *et al.*¹⁴⁰ studied the improved relaxivity of Gd-EMF derivatives deposited on graphene oxide nanosheets (GO-Gd@C₈₂). Their results showed that physicochemical properties and structure are important factors that can affect relaxivity. Additionally, electron transfer between Gd-EMF and the GO sheet was found to aid proton relaxation. This interaction is stronger than that of water and the Gd ions.

Pan *et al.*¹⁴¹ investigated the impact of Gd@C₈₂(OH)₂₂ on epigenetic regulation of human pancreatic cancer metastasis.




Fig. 14 IL-13-Gd₃N@C₈₀(OH)_x(NH₂)_y nanoparticles with positive charges illustrating facile binding to negatively charged phospholipid bilayer cellular surfaces. Reprinted with permission from Li *et al.*¹³⁹ Copyright (2015) American Chemical Society.

From computational and experimental results from both *in vitro* and *in vivo* studies, it was concluded that Gd@C₈₂(OH)₂₂ inhibits histone deacetylase-1 (HDAC-1) and suppresses pancreatic cancer cell invasion and metastasis.

Tang *et al.*¹⁴² investigated the activity of Gd@C₈₂(OH)₂₂ in cancer immunotherapy by regulating macrophage activity. The results showed enhanced macrophage viability, phagocytosis, and secretion of cytokines by macrophages. The activated macrophages inhibited tumor formation and metastasis *in vivo*, and induced cancer cell death *in vitro*, as represented in Fig. 15.

The ability of Gd@C₈₂(OH)₂₂ to activate macrophages was also studied by Chen *et al.*¹⁴³ using synchrotron-based scanning transmission X-ray microscopy (STXM) with a high spatial resolution of 30 nm. Gd@C₈₂(OH)₂₂ significantly activated primary mouse macrophages and produced pro-inflammatory cytokines, evidencing the possible role of these fullerenols in antitumor immune response.




Fig. 15 The possible mechanism by which back transfusion of macrophages activated by Gd@C₈₂(OH)₂₂ nanoparticles inhibits tumor metastasis. Reprinted from Tang *et al.*¹⁴² Copyright (2016), with permission from Elsevier.

9. Future and perspectives

It is evident from the biological and medical applications of functionalized empty and endohedral fullerenes that many studies including toxicity and solubility should be addressed. However, many of the biological experiments are far from practical applications at this point. Most of these fullerene derivatives have yet to prove their efficacy and safety *in vivo*, as most have been conducted *in vitro* with a non-consistent variety of cell types. The compatibility of fullerene derivatives with various biological systems ought to be established before any clinical studies are attempted.

One of the biggest obstacles for the progress of fullerene-based treatments is the elevated cytotoxicity due to their hydrophobic nature, which increases their likelihood of absorbing biological species or accumulating in lipid membranes. However, multiple research studies have presented evidence against this fear, or demonstrated that it can be circumvented *via* modification with biocompatible moieties, as described in this review. Varied cytotoxicity levels and properties are expected for the wide breadth of fullerene derivatives presented in this summary, as their cytotoxic effects depend on different physical properties (size and shape), fabrication methods, and surface functionalization. Systematic toxicological and pharmacokinetic investigations of individual fullerene derivatives are expected to continue and become a more important topic in the field of biomedicine. Beyond studying their therapeutic effects, bioaccumulation studies are just as vital for their eventual translational use.

10. Conclusions

In this short review we have summarized the biological applications of empty as well as of reported endohedral fullerene derivatives during the last 3 years, which include anti-viral, PDT, antioxidant, anticancer, immunological, MRI contrast agents and tumor therapy. Remarkable progress has been made in the biological applications of fullerenes since the first report in 1993. To solve the almost complete insolubility in aqueous media, several synthetic approaches have been developed as discussed in this review.

Given the fast growth of these compounds for different biological applications combined with low toxicity, it is anticipated that many more biomedical applications will be forthcoming for these interesting compounds.

Acknowledgements

L. E. thanks the US National Science Foundation (NSF) for generous support of this work under the NSF-PREM program (DMR 1205302) and the CHE-1408865. The Robert A. Welch Foundation is also gratefully acknowledged for an endowed chair to L. E. (Grant AH-0033). The National Institute of General Medical Sciences of the National Institutes of Health under linked Award Numbers RL5GM118969, TL4GM118971, and UL1GM118970 is also acknowledged.

References

- H. W. Kroto, J. R. Heath, S. C. O'Brien, R. F. Curl and R. E. Smalley, *Nature*, 1985, **318**, 162–163.
- J. M. Hawkins, T. A. Lewis, S. D. Loren, A. Meyer, J. R. Heath, Y. Shibato and R. J. Saykally, *J. Org. Chem.*, 1990, **55**, 6250–6252.
- W. Kratschmer, L. D. Lamb, K. Fostiropoulos and D. R. Huffman, *Nature*, 1990, **347**, 354–358.
- F. Wudl, *Acc. Chem. Res.*, 1992, **25**, 157–161.
- R. Sijbesma, G. Srđanov, F. Wudl, J. A. Castoro, C. Wilkins, S. H. Friedman, D. L. DeCamp and G. L. Kenyon, *J. Am. Chem. Soc.*, 1993, **115**, 6510–6512.
- C. Thilgen and F. Diederich, *Chem. Rev.*, 2006, **106**, 5049–5135.
- M. D. Tzirakis and M. Orfanopoulos, *Chem. Rev.*, 2013, **113**, 5262–5321.
- A. R. Barron, *J. Enzyme Inhib. Med. Chem.*, 2016, **31**, 164–176.
- S. Jennepalli, S. G. Pyne and P. A. Keller, *RSC Adv.*, 2014, **4**, 46383–46398.
- S. J. Vance, V. Desai, B. O. Smith, M. W. Kennedy and A. Cooper, *Biophys. Chem.*, 2016, **214–215**, 27–32.
- S. Bhatia, M. Dimde and R. Haag, *MedChemComm*, 2014, **5**, 862–878.
- A. Muñoz, D. Sigwalt, B. M. Illescas, J. Luczkowiak, L. Rodríguez-Pérez, I. Nierengarten, M. Holler, J.-S. Remy, K. Buffet, S. P. Vincent, J. Rojo, R. Delgado, J.-F. Nierengarten and N. Martín, *Nat. Chem.*, 2016, **8**, 50–57.
- J. Grebowski, P. Kazmierska and A. Krokosz, *BioMed Res. Int.*, 2013, **9**.
- K. N. Semenov, N. A. Charykov, V. N. Postnov, V. V. Sharoyko, I. V. Vorotyntsev, M. M. Galagudza and I. V. Murin, *Prog. Solid State Chem.*, 2016, **44**, 59–74.
- S. S. Ali, J. I. Hardt and L. L. Dugan, *Nanomedicine*, 2008, **4**, 283–294.
- A. B. Kornev, A. S. Peregudov, V. M. Martynenko, J. Balzarini, B. Hoorelbeke and P. A. Troshin, *Chem. Commun.*, 2011, **47**, 8298–8300.
- H. Kataoka, T. Ohe, K. Takahashi, S. Nakamura and T. Mashino, *Bioorg. Med. Chem. Lett.*, 2016, **26**, 4565–4567.
- G. Pastorin, S. Marchesan, J. Hoebeker, T. Da Ros, L. Ehret-Sabatier, J.-P. Briand, M. Prato and A. Bianco, *Org. Biomol. Chem.*, 2006, **4**, 2556–2562.
- E. Castro, Z. S. Martinez, C. S. Seong, A. Cabrera-Espinoza, M. Ruiz, G. Hernandez, A. F. Valdez, M. Llano and L. A. Echegoyen, *J. Med. Chem.*, 2016, **59**, 10963–10973.
- A. Ikeda, *Chem. Rec.*, 2016, **16**, 249–260.
- A. Ikeda, T. Mae, M. Ueda, K. Sugikawa, H. Shigeto, H. Funabashi, A. Kuroda and M. Akiyama, *Chem. Commun.*, 2017, **53**, 2966–2969.
- F. Cantalado and T. Da Ros, *Medicinal Chemistry and Pharmacological Potential of Fullerenes and Carbon Nanotubes*, Springer, 2008, vol. 1, pp. 107–121.
- X. Yang, A. Ebrahimi, J. Li and Q. Cui, *Int. J. Nanomed.*, 2014, **9**, 77–92.
- D. M. Nozdrenko, D. O. Zavodovskiy, T. Y. Matvienko, S. Y. Zay, K. I. Bogutska, Y. I. Pylutskyy, U. Ritter and P. Scharff, *Nanoscale Res. Lett.*, 2017, **12**, 115.

- 25 P. G. Yuliana, A. Igor, Z. Petr, P. Evgenia, M. Maria, B. Anna and C. Vladimir, *Curr. Aging Sci.*, 2017, **10**, 56–67.
- 26 S. J. Vance, V. Desai, B. O. Smith, M. W. Kennedy and A. Cooper, *Biophys. Chem.*, 2016, **214–215**, 27–32.
- 27 S. Bosi, T. Da Ros, G. Spalluto and M. Prato, *Eur. J. Med. Chem.*, 2003, **38**, 913–923.
- 28 R. Bakry, R. M. Vallant, M. Najam-ul-Haq, M. Rainer, Z. Szabo, C. W. Huck and G. K. Bonn, *Int. J. Nanomed.*, 2007, **2**, 639–649.
- 29 A. Hirsch, *Fullerenes and Related Structures*, Springer Berlin Heidelberg, 1999, vol. 199, ch. 1, pp. 1–65.
- 30 M. Yamada, T. Akasaka and S. Nagase, *Chem. Rev.*, 2013, **113**, 7209–7264.
- 31 M. A. Lebedeva, T. W. Chamberlain and A. N. Khlobystov, *Chem. Rev.*, 2015, **115**, 11301–11351.
- 32 M. Prato, *J. Mater. Chem.*, 1997, **7**, 1097–1109.
- 33 Q. Xie, E. Perez-Cordero and L. Echegoyen, *J. Am. Chem. Soc.*, 1992, **114**, 3978–3980.
- 34 H. C. Dorn and J. C. Duchamp, in *Introduction to Nanoscale Science and Technology*, ed. M. Di Ventra, S. Evoy and J. R. Hefflin, Springer US, Boston, MA, 2004, pp. 119–135.
- 35 F. Wudl, A. Hirsch, K. C. Khemani, T. Suzuki, P. M. Allemand, A. Koch, H. Eckert, G. Srdanov and H. M. Webb, *Fullerenes*, American Chemical Society, 1992, vol. 481, ch. 11, pp. 161–175.
- 36 R. E. Smalley and R. F. Curl, *Fullerenes*, Vignyan Scientific American, 1991, ch. 32, pp. 32–41.
- 37 R. S. Ruoff and A. L. Ruoff, *Appl. Phys. Lett.*, 1991, **59**, 1553–1555.
- 38 R. S. Ruoff, D. S. Tse, R. Malhotra and D. C. Lorents, *J. Phys. Chem.*, 1993, **97**, 3379–3383.
- 39 N. Kumarasamy and S. Krishnan, *Curr. Opin. HIV AIDS*, 2013, **8**, 586–590.
- 40 K. Paydary, P. Khaghani, S. Emamzadeh-Fard, S. A. Alinaghi and K. Baesi, *Asian Pac. J. Trop. Biomed.*, 2013, **3**, 515–522.
- 41 M. M. Santoro and C. F. Perno, *ISRN Microbiol.*, 2013, **20**.
- 42 E. Urano, S. D. Ablan, R. Mandt, G. T. Pauly, D. M. Sigano, J. P. Schneider, D. E. Martin, T. J. Nitz, C. T. Wild and E. O. Freed, *Antimicrob. Agents Chemother.*, 2016, **60**, 190–197.
- 43 E. O. Freed, *Nat. Rev. Microbiol.*, 2015, **13**, 484–496.
- 44 S. H. Friedman, D. L. DeCamp, R. P. Sijbesma, G. Srdanov, F. Wudl and G. L. Kenyon, *J. Am. Chem. Soc.*, 1993, **115**, 6506–6509.
- 45 Z. S. Martinez, E. Castro, C. S. Seong, M. R. Ceron, L. Echegoyen and M. Llano, *Antimicrob. Agents Chemother.*, 2016, **60**, 5731–5741.
- 46 C. Toniolo, A. Bianco, M. Maggini, G. Scorrano, M. Prato, M. Marastoni, R. Tomatis, S. Spisani, G. Palu and E. D. Blair, *J. Med. Chem.*, 1994, **37**, 4558–4562.
- 47 S. Durdagi, C. T. Supuran, T. A. Strom, N. Doostdar, M. K. Kumar, A. R. Barron, T. Mavromoustakos and M. G. Papadopoulos, *J. Chem. Inf. Model.*, 2009, **49**, 1139–1143.
- 48 T. A. Strom, S. Durdagi, S. S. Ersoz, R. E. Salmas, C. T. Supuran and A. R. Barron, *J. Pept. Sci.*, 2015, **21**, 862–870.
- 49 E. A. Khakina, O. G. A. Kraevaya, M. L. Popova, A. S. Peregudov, S. I. Troyanov, A. V. Chernyak, V. M. Martynenko, A. V. Kulikov, D. Schols and P. A. Troshin, *Org. Biomol. Chem.*, 2017, **15**, 773–777.
- 50 E. A. Khakina, A. A. Yurkova, A. S. Peregudov, S. I. Troyanov, V. V. Trush, A. I. Vovk, A. V. Mumyatov, V. M. Martynenko, J. Balzarini and P. A. Troshin, *Chem. Commun.*, 2012, **48**, 7158–7160.
- 51 S. Nakamura and T. Mashino, *J. Nippon Med. Sch.*, 2012, **79**, 248–254.
- 52 T. Yasuno, T. Ohe, K. Takahashi, S. Nakamura and T. Mashino, *Bioorg. Med. Chem. Lett.*, 2015, **25**, 3226–3229.
- 53 M. C. Galan, P. Dumy and O. Renaudet, *Chem. Soc. Rev.*, 2013, **42**, 4599–4612.
- 54 J.-F. Nierengarten, J. Iehl, V. Oerthel, M. Holler, B. M. Illescas, A. Munoz, N. Martin, J. Rojo, M. Sanchez-Navarro, S. Cecioni, S. Vidal, K. Buffet, M. Durka and S. P. Vincent, *Chem. Commun.*, 2010, **46**, 3860–3862.
- 55 M. Sánchez-Navarro, A. Muñoz, B. M. Illescas, J. Rojo and N. Martín, *Chem. – Eur. J.*, 2011, **17**, 766–769.
- 56 K. Buffet, E. Gillon, M. Holler, J.-F. Nierengarten, A. Imberty and S. P. Vincent, *Org. Biomol. Chem.*, 2015, **13**, 6482–6492.
- 57 W. Na, N. Park, M. Yeom and D. Song, *Clin. Exp. Vaccine Res.*, 2015, **4**, 17–22.
- 58 World-Health-Organization, Ebola data and statistics, <http://apps.who.int/gho/data/view ebola-sitrep ebola-summary-latest?lang=en>, accessed February 27th, 2017.
- 59 J. E. Carette, M. Raaben, A. C. Wong, A. S. Herbert, G. Obernosterer, N. Mulherkar, A. I. Kuehne, P. J. Kranzusch, A. M. Griffin, G. Ruthel, P. D. Cin, J. M. Dye, S. P. Whelan, K. Chandran and T. R. Brummelkamp, *Nature*, 2011, **477**, 340–343.
- 60 K. D. McReynolds and J. Gervay-Hague, *Chem. Rev.*, 2007, **107**, 1533–1552.
- 61 I. Nierengarten and J. F. Nierengarten, *Chem. – Asian J.*, 2014, **9**, 1436–1444.
- 62 A. Tikad, H. Fu, C. M. Sevrain, S. Laurent, J.-F. Nierengarten and S. P. Vincent, *Chem. – Eur. J.*, 2016, **22**, 13147–13155.
- 63 M. Abellán Flos, M. I. García Moreno, C. Ortiz Mellet, J. M. García Fernández, J.-F. Nierengarten and S. P. Vincent, *Chem. – Eur. J.*, 2016, **22**, 11450–11460.
- 64 F. Stauffert, A. Bodlenner, T. M. Nguyet Trinh, M. I. Garcia-Moreno, C. Ortiz Mellet, J.-F. Nierengarten and P. Compain, *New J. Chem.*, 2016, **40**, 7421–7430.
- 65 J. Luczkowiak, A. Muñoz, M. Sánchez-Navarro, R. Ribeiro-Viana, A. Ginieis, B. M. Illescas, N. Martín, R. Delgado and J. Rojo, *Biomacromolecules*, 2013, **14**, 431–437.
- 66 S. Gross, A. Gilead, A. Scherz, M. Neeman and Y. Salomon, *Nat. Med.*, 2003, **9**, 1327–1331.
- 67 M. Broekgaarden, R. Weijer, T. M. van Gulik, M. R. Hamblin and M. Heger, *Cancer Metastasis Rev.*, 2015, **34**, 643–690.
- 68 Z. Zhen, W. Tang, C. Guo, H. Chen, X. Lin, G. Liu, B. Fei, X. Chen, B. Xu and J. Xie, *ACS Nano*, 2013, **7**, 6988–6996.
- 69 J. W. Arbogast, A. P. Darmanyan, C. S. Foote, F. N. Diederich, R. L. Whetten, Y. Rubin, M. M. Alvarez and S. J. Anz, *J. Phys. Chem.*, 1991, **95**, 11–12.
- 70 Y. Yamakoshi, N. Umezawa, A. Ryu, K. Arakane, N. Miyata, Y. Goda, T. Masumizu and T. Nagano, *J. Am. Chem. Soc.*, 2003, **125**, 12803–12809.

- 71 L. Huang, M. Wang, T. Dai, F. F. Sperandio, Y.-Y. Huang, Y. Xuan, L. Y. Chiang and M. R. Hamblin, *Nanomedicine*, 2013, **9**, 253–266.
- 72 Y. Zhang, T. Dai, M. Wang, D. Vecchio, L. Y. Chiang and M. R. Hamblin, *Nanomedicine*, 2015, **10**, 603–614.
- 73 Z. Lu, T. Dai, L. Huang, D. B. Kurup, G. P. Tegos, A. Jahnke, T. Wharton and M. R. Hamblin, *Nanomedicine*, 2010, **5**, 1525–1533.
- 74 P. Mroz, G. P. Tegos, H. Gali, T. Wharton, T. Sarna and M. R. Hamblin, *Photochem. Photobiol. Sci.*, 2007, **6**, 1139–1149.
- 75 C. Yu, P. Avci, T. Canteenwala, L. Y. Chiang, B. J. Chen and M. R. Hamblin, *J. Nanosci. Nanotechnol.*, 2016, **16**, 171–181.
- 76 M. Guan, J. Ge, J. Wu, G. Zhang, D. Chen, W. Zhang, Y. Zhang, T. Zou, M. Zhen, C. Wang, T. Chu, X. Hao and C. Shu, *Biomaterials*, 2016, **103**, 75–85.
- 77 Q. Li, C. Liu and H. Li, *J. Nanosci. Nanotechnol.*, 2016, **16**, 5592–5597.
- 78 S. Kim, D. J. Lee, D. S. Kwag, U. Y. Lee, Y. S. Youn and E. S. Lee, *Carbohydr. Polym.*, 2014, **101**, 692–698.
- 79 D. Franskevych, K. Palyvoda, D. Petukhov, S. Prylutska, I. Grynyuk, C. Schuetze, L. Drobot, O. Matyshevska and U. Ritter, *Nanoscale Res. Lett.*, 2017, **12**, 40.
- 80 G. Mion, C. Mari, T. Da Ros, R. Rubbiani, G. Gasser and T. Gianferrara, *ChemistrySelect*, 2017, **2**, 190–200.
- 81 E. S. Ershova, V. A. Sergeeva, A. I. Chausheva, D. G. Zheglo, V. A. Nikitina, T. D. Smirnova, L. V. Kameneva, L. N. Porokhovnik, S. I. Kutsev, P. A. Troshin, I. I. Voronov, E. A. Khakina, N. N. Veiko and S. V. Kostyuk, *Mutat. Res., Fundam. Mol. Mech. Mutagen.*, 2016, **805**, 46–57.
- 82 C. R. Miller, B. Bondurant, S. D. McLean, K. A. McGovern and D. F. O'Brien, *Biochemistry*, 1998, **37**, 12875–12883.
- 83 J. Wang, Z. Zhang, W. Wu and X. Jiang, *Chin. J. Chem.*, 2014, **32**, 78–84.
- 84 A. Djordjevic, R. Injac, D. Jovic, J. Mrdjanovic and M. Seke, *Advanced Carbon Materials and Technology*, John Wiley & Sons, Inc., 2014, pp. 193–271.
- 85 F. Caputo, M. De Nicola and L. Ghibelli, *Biochem. Pharmacol.*, 2014, **92**, 112–130.
- 86 A. Lichota and A. Krokosz, *Med. Pr.*, 2016, **67**, 817–831.
- 87 L. Xiao, H. Takada, X. H. Gan and N. Miwa, *Bioorg. Med. Chem. Lett.*, 2006, **16**, 1590–1595.
- 88 P. J. Krusic, E. Wasserman, P. N. Keizer, J. R. Morton and K. F. Preston, *Science*, 1991, **254**, 1183–1185.
- 89 A. Krokosz, A. Lichota, K. E. Nowak and J. Grebowski, *Radiat. Phys. Chem.*, 2016, **128**, 143–150.
- 90 A. Djordjevic, B. Srdjenovic, M. Seke, D. Petrovic, R. Injac and J. Mrdjanovic, *J. Nanomater.*, 2015, **2015**, 15.
- 91 J. Li, M. Guan, T. Wang, M. Zhen, F. Zhao, C. Shu and C. Wang, *ACS Appl. Mater. Interfaces*, 2016, **8**, 25770–25776.
- 92 V. Jacevic, A. Djordjevic, B. Srdjenovic, V. Milic-Tores, Z. Segrt, V. Dragojevic-Simic and K. Kuca, *Exp. Mol. Pathol.*, 2017, **102**, 360–369.
- 93 P. Ghasemzadeh, S. M. Rezaayat, S. Adeli and N. Rahbar-Roshandel, *Acta Med. Iran.*, 2016, **7**.
- 94 J. R. Vani, M. T. Mohammadi, M. S. Foroshani and M. Jafari, *EXCLI J.*, 2016, **15**, 378–390.
- 95 J. Huang, C. Zhou, J. He, Z. Hu, W.-c. Guan and S.-h. Liu, *J. Huazhong Univ. Sci. Technol., Med. Sci.*, 2016, **36**, 356–363.
- 96 T. Wakimoto, K. Uchida, K. Mimura, T. Kanagawa, T. R. Mehandjiev, H. Aoshima, K. Kokubo, N. Mitsuda, Y. Yoshioka, Y. Tsutsumi, T. Kimura and I. Yanagihara, *Am. J. Obstet. Gynecol.*, 2015, **213**, 708.e701–708.e709.
- 97 X. Yang, C.-J. Li, Y. Wan, P. Smith, G. Shang and Q. Cui, *Int. J. Nanomed.*, 2014, **9**, 4023–4031.
- 98 S. Kato, H. Aoshima, Y. Saitoh and N. Miwa, *Bioorg. Med. Chem. Lett.*, 2009, **19**, 5293–5296.
- 99 Z. Wang, X. Chang, Z. Lu, M. Gu, Y. Zhao and X. Gao, *Chem. Sci.*, 2014, **5**, 2940–2948.
- 100 H. Ueno, S. Yamakura, R. S. Arastoo, T. Oshima and K. Kokubo, *J. Nanomater.*, 2014, **7**.
- 101 J. Grebowski, A. Krokosz, A. Konarska, M. Wolszczak and M. Puchala, *Radiat. Phys. Chem.*, 2014, **103**, 146–152.
- 102 D. M. Guldi and K.-D. Asmus, *Radiat. Phys. Chem.*, 1999, **56**, 449–456.
- 103 B. Srđenović, M. Slavić, K. Stankov, N. Kladar, D. Jović, M. Seke and V. Bogdanović, *Hem. Ind.*, 2015, **69**, 425–431.
- 104 F. Awan, E. Bulger, R. M. Berry and K. C. Tam, *Cellulose*, 2016, **23**, 3589–3599.
- 105 L.-Y. Yang, J.-L. Gao, T. Gao, P. Dong, L. Ma, F.-L. Jiang and Y. Liu, *J. Hazard. Mater.*, 2016, **301**, 119–126.
- 106 M. Sun, A. Kiourti, H. Wang, S. Zhao, G. Zhao, X. Lu, J. L. Volakis and X. He, *Mol. Pharmaceutics*, 2016, **13**, 2184–2192.
- 107 H. Wang, P. Agarwal, S. Zhao, J. Yu, X. Lu and X. He, *Biomaterials*, 2016, **97**, 62–73.
- 108 F.-Y. Hsieh, A. V. Zhilenkov, I. I. Voronov, E. A. Khakina, D. V. Mischenko, P. A. Troshin and S.-h. Hsu, *ACS Appl. Mater. Interfaces*, 2017, **9**, 11482–11492.
- 109 G. Wu, X. J. Gao, J. Jang and X. Gao, *J. Mol. Model.*, 2016, **22**, 161.
- 110 S. V. Prylutska, L. M. Skivka, G. V. Didenko, Y. I. Prylutsky, M. P. Evstigneev, G. P. Potebnya, R. R. Panchuk, R. S. Stoika, U. Ritter and P. Scharff, *Nanoscale Res. Lett.*, 2015, **10**, 499.
- 111 K. Raza, N. Thotakura, P. Kumar, M. Joshi, S. Bhushan, A. Bhatia, V. Kumar, R. Malik, G. Sharma, S. K. Guru and O. P. Katore, *Int. J. Pharm.*, 2015, **495**, 551–559.
- 112 H. Zhang, L. Hou, X. Jiao, Y. Ji, X. Zhu and Z. Zhang, *Biomaterials*, 2015, **37**, 353–366.
- 113 T. Watanabe, S. Nakamura, T. Ono, S. Ui, S. Yagi, H. Kagawa, H. Watanabe, T. Ohe, T. Mashino and M. Fujimuro, *Biochem. Biophys. Res. Commun.*, 2014, **451**, 93–100.
- 114 C. Nishizawa, N. Hashimoto, S. Yokoo, M. Funakoshi-Tago, T. Kasahara, K. Takahashi, S. Nakamura and T. Mashino, *Free Radical Res.*, 2009, **43**, 1240–1247.
- 115 M. Funakoshi-Tago, M. Tsukada, T. Watanabe, Y. Mameda, K. Tago, T. Ohe, S. Nakamura, T. Mashino and T. Kasahara, *Int. Immunopharmacol.*, 2014, **20**, 258–263.
- 116 S. Prylutska, I. Grynyuk, O. Matyshevska, Y. Prylutsky, M. Evstigneev, P. Scharff and U. Ritter, *Drugs R&D*, 2014, **14**, 333–340.
- 117 G. E. Magoulas, M. Bantzi, D. Messari, E. Voulgari, C. Gialeli, D. Barbouri, A. Giannis, N. K. Karamanos,

- D. Papaioannou and K. Avgoustakis, *Pharm. Res.*, 2015, **32**, 1676–1693.
- 118 I. Yumiko, N. Koji, F. Junya, F. Toshio, Y. Nagahiko, I. Toshihiko, C. Fu-shin, M. Yasunori and U. Shin-ichiro, *Jpn. J. Appl. Phys.*, 2016, **55**, 07KF02.
- 119 B. X. Chen, S. R. Wilson, M. Das, D. J. Coughlin and B. F. Erlanger, *Proc. Natl. Acad. Sci. U. S. A.*, 1998, **95**, 10809–10813.
- 120 N. Shershakova, E. Baraboshkina, S. Andreev, D. Purgina, I. Struchkova, O. Kamyshnikov, A. Nikonova and M. Khaitov, *J. Nanobiotechnol.*, 2016, **14**, 8.
- 121 B. C. Braden, F. A. Goldbaum, B.-X. Chen, A. N. Kirschner, S. R. Wilson and B. F. Erlanger, *Proc. Natl. Acad. Sci. U. S. A.*, 2000, **97**, 12193–12197.
- 122 D. Petrovic, M. Seke, B. Srdjenovic and A. Djordjevic, *J. Nanomater.*, 2015, **2015**, 11.
- 123 M. Turabekova, B. Rasulev, M. Theodore, J. Jackman, D. Leszczynska and J. Leszczynski, *Nanoscale*, 2014, **6**, 3488–3495.
- 124 T. Hirai, Y. Yoshioka, A. Udaka, E. Uemura, T. Ohe, H. Aoshima, J.-Q. Gao, K. Kokubo, T. Oshima, K. Nagano, K. Higashisaka, T. Mashino and Y. Tsutsumi, *Nanoscale Res. Lett.*, 2016, **11**, 449.
- 125 M. Funakoshi-Tago, Y. Miyagawa, F. Ueda, T. Mashino, Y. Moriwaki, K. Tago, T. Kasahara and H. Tamura, *Int. Immunopharmacol.*, 2016, **40**, 254–264.
- 126 A. M. Miller, *J. Inflammation*, 2011, **8**, 22.
- 127 N. T. Martin and M. U. Martin, *Nat. Immunol.*, 2016, **17**, 122–131.
- 128 S. Wang, L. Ding, S.-S. Liu, C. Wang, R.-X. Leng, G.-M. Chen, Y.-G. Fan, H.-F. Pan and D.-Q. Ye, *J. Invest. Med.*, 2012, **60**, 1151–1156.
- 129 S. Pacor, A. Grillo, L. Đorđević, S. Zorzet, M. Lucafò, T. Da Ros, M. Prato and G. Sava, *BioMed Res. Int.*, 2015, **13**.
- 130 T. Li and H. C. Dorn, *Small*, 2016, **13**, 1603152.
- 131 H. Kato, Y. Kanazawa, M. Okumura, A. Taninaka, T. Yokawa and H. Shinohara, *J. Am. Chem. Soc.*, 2003, **125**, 4391–4397.
- 132 R. Cui, J. Li, H. Huang, M. Zhang, X. Guo, Y. Chang, M. Li, J. Dong, B. Sun and G. Xing, *Nano Res.*, 2015, **8**, 1259–1268.
- 133 L. Wang, X. Zhu, X. Tang, C. Wu, Z. Zhou, C. Sun, S.-L. Deng, H. Ai and J. Gao, *Chem. Commun.*, 2015, **51**, 4390–4393.
- 134 Y. Zhang, T. Zou, M. Guan, M. Zhen, D. Chen, X. Guan, H. Han, C. Wang and C. Shu, *ACS Appl. Mater. Interfaces*, 2016, **8**, 11246–11254.
- 135 S. V. Murphy, A. Hale, T. Reid, J. Olson, A. Kidiyoor, J. Tan, Z. Zhou, J. Jackson and A. Atala, *Methods*, 2016, **99**, 99–111.
- 136 J. Zhang, Y. Ye, Y. Chen, C. Pregot, T. Li, S. Balasubramaniam, D. B. Hobart, Y. Zhang, S. Wi, R. M. Davis, L. A. Madsen, J. R. Morris, S. M. LaConte, G. T. Yee and H. C. Dorn, *J. Am. Chem. Soc.*, 2014, **136**, 2630–2636.
- 137 J. Li, T. Wang, Y. Feng, Y. Zhang, M. Zhen, C. Shu, L. Jiang, Y. Wang and C. Wang, *Dalton Trans.*, 2016, **45**, 8696–8699.
- 138 L. Xiao, T. Li, M. Ding, J. Yang, J. Rodríguez-Corrales, S. M. LaConte, N. Nacey, D. B. Weiss, L. Jin, H. C. Dorn and X. Li, *Bioconjugate Chem.*, 2017, **28**, 649–658.
- 139 T. Li, S. Murphy, B. Kiselev, K. S. Bakshi, J. Zhang, A. Eltahir, Y. Zhang, Y. Chen, J. Zhu, R. M. Davis, L. A. Madsen, J. R. Morris, D. R. Karolyi, S. M. LaConte, Z. Sheng and H. C. Dorn, *J. Am. Chem. Soc.*, 2015, **137**, 7881–7888.
- 140 J. Li, R. Cui, Y. Chang, X. Guo, W. Gu, H. Huang, K. Chen, G. Lin, J. Dong, G. Xing and B. Sun, *RSC Adv.*, 2016, **6**, 58028–58033.
- 141 Y. Pan, L. Wang, S.-g. Kang, Y. Lu, Z. Yang, T. Huynh, C. Chen, R. Zhou, M. Guo and Y. Zhao, *ACS Nano*, 2015, **9**, 6826–6836.
- 142 J. Tang, Z. Chen, B. Sun, J. Dong, J. Liu, H. Zhou, L. Wang, R. Bai, Q. Miao, Y. Zhao, C. Chen and Y. Liu, *Nanomedicine*, 2016, **12**, 945–954.
- 143 Z. Chen, Y. Liu, B. Sun, H. Li, J. Dong, L. Zhang, L. Wang, P. Wang, Y. Zhao and C. Chen, *Small*, 2014, **10**, 2362–2372.